Demand for antibodies is anticipated to remain steady across the globe in the foreseeable future. Rising occurrence of chronic diseases such as diabetes, cancer, and autoimmune conditions is prompting drug makers to shift their focus on further improvement of antibody-based products. Moreover, increasing prevalence of epidemic diseases as well as rising popularity of protein therapeutics is reflecting favourably on antibody-based drug sales worldwide. In developed regions such as North America and Europe demand for antibody-based medicines is projected to remain steady over the next couple of years. On the other hand, increasing availability of alternative therapeutics is likely to make a negative impact on the growth of the global antibodies market. In addition, factors such as unaffordability and risk of side effects associated with antibody products are likely underwhelm the future prospects of the overall market. The recent study conducted by Fact. MR projects that global market for antibodies will cross a valuation of US$ 3,000 Mn by 2022-end, registering a moderate CAGR during the forecast period (2017-2022).